Acuta Capital Partners’s Arbutus Biopharma ABUS Stock Holding History

Acuta Capital Partners’s Portfolio ABUS Stock Details ABUS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-269,907	Closed	-$273K	–	47
2020 Q1	$273K	Buy	+269,907	New	+$730K	0.13%	32

Other funds holding ABUS

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

CAC

Cowen and Company New York $2.97B AUM 105.26% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Bank of Montreal Toronto, Ontario, Canada $269B AUM 31.4% 1-Year Est. Return

Acuta Capital Partners's ABUS Position: Q2 2020 in Review

Acuta Capital Partners sold out of Arbutus Biopharma (ABUS) in Q2 2020, closing a stake of 269,907 shares — an estimated $273K sold.

Acuta Capital Partners first reported a position in ABUS in Q1 2020 and held it in 1 quarter. The position peaked at $273K in Q1 2020. 51 funds tracked by Wall St. Rank hold ABUS as of Q2 2020.

Acuta Capital Partners reported no remaining Arbutus Biopharma position as of Q2 2020 after selling out during the quarter.
Acuta Capital Partners sold 269,907 Arbutus Biopharma shares in Q2 2020, an estimated $273K.
Acuta Capital Partners first reported a position in Arbutus Biopharma in Q1 2020 and held it in 1 quarter.
Acuta Capital Partners's Arbutus Biopharma position peaked at $273K in Q1 2020.
51 funds tracked by Wall St. Rank held Arbutus Biopharma as of Q2 2020.

Based on Acuta Capital Partners's 13F filing for Q2 2020, filed 14 Aug 2020.